VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CAMP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CAMPCAMP4 Therapeutics Corporation
$4.40$93M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

CAMP logoCAMP4 Therapeutics Corporation(CAMP)Earnings, Financials & Key Ratios

CAMP•NASDAQ
$4.40
Price updated Jul 7, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryRNA and Genome Editing Developers
AboutCAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.Show more
  • Revenue$3M+436.5%
  • EBITDA-$50M+1.9%
  • Net Income-$80M-55.2%
  • EPS (Diluted)-2.65+0.4%
  • Gross Margin53.14%-46.9%
  • EBITDA Margin-1441.45%+81.7%
  • Operating Margin-1488.31%+81.7%
  • Net Margin-2298.54%+71.1%
  • ROE-145.07%-76.9%

CAMP Price & Volume

CAMP4 Therapeutics Corporation (CAMP) stock price & volume — 10-year historical chart

Loading chart...

Clinical Development Costs Outpace Volatile Revenue Streams

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Clinical trial execution failure

Key Thesis Takeaways

  • CAMP4 Therapeutics remains in a high-risk, early-stage development phase where the proprietary regRNA platform serves as the primary value driver despite the absence of recurring commercial revenue.
  • While the company has successfully bolstered its liquidity to $99.2M as of 2026Q1, the structural reliance on external capital to fund quarterly R&D expenditures of approximately $9.6M creates significant long-term dilution risk.
  • Investors should monitor the firm's ability to transition from project-dependent milestone payments to a sustainable clinical pipeline, as the current net loss trajectory of $18.3M per quarter necessitates continued capital market access.

Verdict Logic

the company's extreme operating margin of -10.1% and persistent quarterly net losses of $18.3M suggest that the firm remains years away from self-sustaining profitability.

CAMP Growth Metrics

CAMP4 Therapeutics Corporation (CAMP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-35.5%
5 Years-59.18%
3 Years-
TTM160.53%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-66.69%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM19.22%

Return on Capital

10 Years-25.07%
5 Years-50.58%
3 Years-75.25%
Last Year-60.89%

CAMP Recent Earnings

CAMP4 Therapeutics Corporation (CAMP) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 5/12 qtrs (63%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$0.32-52.4%
$0.21
Rev
$1M+15.7%
$1M
Q2 2026
Mar 5, 2026
Metric
Actual
Est
EPS
$0.87-180.6%
$0.31
Rev
$300,000-36.9%
$475,200
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$0.55-17.0%
$0.47
Rev
$795,000+83.5%
$433,333
Q3 2025
Aug 14, 2025
Metric
Actual
Est
EPS
$0.62+7.5%
$0.67
Rev
$1M+1069.5%
$128,000
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$0.32vs $0.21-52.4%
$1Mvs $1M+15.7%
Q2 2026Mar 5, 2026
$0.87vs $0.31-180.6%
$300,000vs $475,200-36.9%
Q4 2025Nov 6, 2025
$0.55vs $0.47-17.0%
$795,000vs $433,333+83.5%
Q3 2025Aug 14, 2025
$0.62vs $0.67+7.5%
$1Mvs $128,000+1069.5%
Based on last 12 quarters of dataView full earnings history →

Latest CAMP News

Recent stock market news and headlines for CAMP4 Therapeutics Corporation (CAMP)

GlobeNewsWire·Jun 19, 2026
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company's common stock to three newly hired employees of the Company, each as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).

Globe News Wire·Jun 19, 2026
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. , June 19, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on June 15, 2026 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 39,000 shares of the Company's common stock to three newly hired employees of the Company, each as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the "Inducement Grants").

GlobeNewsWire·Jun 16, 2026
Discovr Radio to Embed Across All Four Days of CAMP Toronto in First Major Activation with Beatcave

Live demo listening session to approve artists onto the platform in real time New “golden ticket” subscriptions reward breakout performers on the spot Studio takeover and on-site activations give creators direct access to Discovr Radio's AI powered artist promotion tools BOULDER, Colo., June 16, 2026 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), an AI first technology company that has built a proprietary AI platform for audio identification and classification to reinvent how consumers engage with audio and how artists get discovered, today announced that its Discovr Radio AI powered artist promotion platform will integrate across all four days of CAMP Toronto, the flagship songwriting camp and music conference hosted by partner Beatcave, taking place July 16-19, 2026.

Peers Comparison

Key metrics vs top competitors for CAMP4 Therapeutics Corporation (CAMP)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
CAMP logoCAMPCAMP4 Therapeutics CorporationCurrent
$4.40$93.46M-1.66436.5%-2298.54%-145.07%—
RARE logoRAREUltragenyx Pharmaceutical Inc.
$35.87$3.53B-6.1520.13%-91.03%——
FOLD logoFOLDAmicus Therapeutics, Inc.
$14.49$4.55B-164.8520.05%-4.27%-12.02%—
ACAD logoACADACADIA Pharmaceuticals Inc.
$26.20$4.49B11.4411.87%34.3%35.65%—
PTCT logoPTCTPTC Therapeutics, Inc.
$89.20$7.4B11.47114.51%-22.58%——
KRYS logoKRYSKrystal Biotech, Inc.
$368.60$10.87B53.8933.94%53.92%19.25%—

Compare CAMP vs Peers

CAMP4 Therapeutics Corporation (CAMP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RARE

Most directly comparable listed peer for CAMP.

Scale Benchmark

vs TMO

Larger-name benchmark to compare CAMP against a more recognizable public peer.

Peer Set

Compare Top 5

vs RARE, FOLD, ACAD, PTCT

CAMP SEC Filings & Documents

CAMP4 Therapeutics Corporation (CAMP) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 14, 2026·SEC

Material company update

May 7, 2026·SEC

Material company update

Mar 24, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 5, 2026·SEC

FY 2025

Mar 27, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

May 7, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 14, 2025·SEC

Get notified when CAMP posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

CAMP Frequently Asked Questions

CAMP4 Therapeutics Corporation (CAMP) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is CAMP4 Therapeutics Corporation's revenue?

CAMP4 Therapeutics Corporation (CAMP) reported $3.9M in revenue for fiscal year 2025. This represents a 92% decrease from $49.3M in 1996.

How fast is CAMP4 Therapeutics Corporation growing?

CAMP4 Therapeutics Corporation (CAMP) grew revenue by 436.5% over the past year. This is strong growth.

Is CAMP profitable?

CAMP4 Therapeutics Corporation (CAMP) reported a net loss of $86.3M for fiscal year 2025.

Dividend & Returns
What is CAMP's return on equity?

CAMP4 Therapeutics Corporation (CAMP) has a return on equity (ROE) of -145.1%. Negative ROE indicates the company is unprofitable.

What is CAMP4 Therapeutics Corporation's free cash flow?

CAMP4 Therapeutics Corporation (CAMP) had negative free cash flow of $26.2M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in CAMP back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →